Cargando…

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study

PURPOSE: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). METHODS: This open-label, prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothschild, Sacha I., Betticher, Daniel, Zenhäusern, Reinhard, Anchisi, Sandro, von Moos, Roger, Pless, Miklos, Moosmann, Peter, Popescu, Razvan A., Calderoni, Antonello, Dressler, Marco, Rauch, Daniel, Pederiva, Stefanie, Woelky, Regina, Papet, Claudia, Bühler, Vera, Borner, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768912/
https://www.ncbi.nlm.nih.gov/pubmed/31444619
http://dx.doi.org/10.1007/s00280-019-03927-x
Descripción
Sumario:PURPOSE: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). METHODS: This open-label, prospective observational study was conducted in Switzerland. RESULTS: A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.3 years; 73.6% males). The frequency of acneiform rash grade ≥ 2 increased from 12.6% at week 2 to 21.7% at week 16. The proportion of patients who reported no skin reaction decreased from 75.6% at week 2 to 43.3% at week 16. The most frequently used skin products at any time of observation were moisturizing (77.6%), lipid-regenerating (56.8%) or urea-containing products (52%), systemic antibiotics (49.6%), and vitamin K1 cream (43.2%). There was no clear effectiveness pattern for all product classes: in given patients, either the product showed no effect at all or a moderate/strong effect, consistently over time. CONCLUSIONS: A great variety of low-cost general skin care products were commonly used. According to physician’s preference, systemic antibiotics and vitamin K1 cream are an appropriate approach to prevent or treat cetuximab-related skin toxicity.